Andrew N. Wilner, MD, FACP, FAAN, a Neurohospitalist at Lawrence and Memorial Hospital, discusses the practice of genetic testing in epilepsy for determining diagnostics and treatment.
Genetic testing can reveal syndromes such as Dravet’s Syndrome (Severe myoclonic epilepsy in infancy) and tuberous sclerosis, and can guide treatment decisions.

Disclosure:

Owns stock, stock options, or bonds from: GlaxoSmithKline

For more information on Dr. Wilner, Please visit:

www.DrWilner.org